CNS: Fenetresurcours: NewsRenderer
Group by:
Date (Most Recent First)
Industry
Subject
Region
Go
Today is July 01, 2024. All times in Eastern Daylight Time.
Riassunto: Denodo integra i microservizi di inferenza NVIDIA NIM per accelerare e ottimizzare le capacità AI per le imprese
06/02/2024 - 07:56 PM
PALO ALTO, Calif.--(BUSINESS WIRE)--Denodo, un leader nella gestione dei dati, ha annunciato di aver integrato i microservizi di inferenza NVIDIA NIM nella Piattaforma Denodo, parte della sua conce...
more
»
Samenvatting: Denodo opent regionaal hoofdkantoor in het Midden-Oosten in Saoedi-Arabië om te voldoen aan de groeiende vraag naar datamanagement en AI
06/02/2024 - 07:55 PM
RIYADH, Saudi-Arabië--(BUSINESS WIRE)--Denodo, een leider in gegevensbeheer, opent vandaag zijn nieuwe regionale hoofdkantoor in het Midden-Oosten in Riyad, het Koninkrijk Saudi-Arabië (KSA). Denod...
more
»
Denodo integriert NVIDIA NIM Inference Microservices für die Beschleunigung und Optimierung von KI-Funktionen für Unternehmen
06/02/2024 - 07:46 PM
PALO ALTO (Kalifornien/USA)--(BUSINESS WIRE)--Denodo, ein führender Anbieter im Bereich Datenmanagement, meldete die Integration von NVIDIA NIM Inference Microservices in die Denodo-Plattform, um s...
more
»
Denodo intègre les microservices d'inférence NIM de NVIDIA pour accélérer et optimiser les capacités d'IA pour les entreprises
06/02/2024 - 07:39 PM
PALO ALTO, Californie--(BUSINESS WIRE)--Denodo, un chef de file de la gestion des données, annonce avoir intégré les microservices d'inférence NIM de NVIDIA à la plateforme Denodo, dans le cadre de...
more
»
Samenvatting: Denodo integreert NVIDIA NIM Inference Microservices om AI-mogelijkheden voor ondernemingen te versnellen en te optimaliseren
06/02/2024 - 07:08 PM
PALO ALTO, Calif.--(BUSINESS WIRE)--Denodo, een leider in gegevensbeheer, heeft aangekondigd dat het NVIDIA NIM inference microservices heeft geïntegreerd in het Denodo-platform, als onderdeel van ...
more
»
Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
06/02/2024 - 07:00 PM
TAIPEI, Taiwan--(BUSINESS WIRE)--The Thunderbolt Go Dock, now with the added capability of Thunderbolt Share for the added benefit of quick PC-to-PC exchange.
more
»
New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
06/02/2024 - 06:00 PM
LONDON--(BUSINESS WIRE)--A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown. A team from The In...
more
»
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
06/02/2024 - 05:30 PM
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bis...
more
»
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
06/02/2024 - 02:32 PM
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meanin...
more
»
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
06/02/2024 - 12:30 PM
MUNICH--(BUSINESS WIRE)--CatalYm today announced positive new follow-up results from its ongoing “GDFATHER” Phase 1/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1/2a) (NC...
more
»
Stronger Than Ever: Adani Portfolio Delivers Record Performance
06/02/2024 - 12:09 PM
AHMEDABAD, India--(BUSINESS WIRE)--Adani Portfolio’s Credit and Result compendium for financial year 2023-24 signify its businesses' strength, stability, and robustness.
more
»
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
06/02/2024 - 10:56 AM
PHILADELPHIA--(BUSINESS WIRE)--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma
more
»
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
06/02/2024 - 10:01 AM
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
more
»
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
06/02/2024 - 09:30 AM
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumo...
more
»
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
06/02/2024 - 09:00 AM
SECAUCUS, N.J.--(BUSINESS WIRE)--ZT Systems, a leading provider of accelerated computing solutions for artificial intelligence (AI) and cloud, today announced its ACX200 platform featuring the NVID...
more
»
1
...
924
925
926
927
928
929
930
931
932
933
934
« Previous
Next »
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire